During the past 3 years, the average EBITDA Per Share Growth Rate was -10.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Global Blood Therapeutics was 2.40% per year. The lowest was -52.60% per year. And the median was -15.65% per year.
Competitive Comparison of Global Blood Therapeutics's 5-Year EBITDA Growth Rate
For the Biotechnology subindustry, Global Blood Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Blood Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's 5-Year EBITDA Growth Rate falls into.
Global Blood Therapeutics 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Global Blood Therapeutics (NAS:GBT) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Global Blood Therapeutics 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Global Blood Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Global Blood Therapeutics (Global Blood Therapeutics) Business Description
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBT has been successfully added to your